>
						产品中心 >
						Cell_transfection >
						Signagen/GenJet In Vitro DNA Transfection Reagent for K562 Cells/SL100489-K562/0.5 mL
					 
								Description
GenJet DNA In Vitro 
Transfection Reagent for K562 is pre-optimized for transfecting 
K562 cells.  
K562 cells were the first human immortalised myelogenous leukaemia line to be 
established and are a bcr:abl positive erythroleukamia line derived from a 53 
year old female CML patient in blast crisis. The cells are non-adherent and 
rounded, and bear some proteomic resemblance to both undifferentiated 
granulocytes and erythrocytes. In culture they exhibit much less clumping than 
many other suspension lines, presumably due to the downregulation of surface 
adhesion molecules by bcr:abl. K562s can spontaneously develop characteristics 
similar to early-stage erythrocytes, granulocytes and monocytes and are easily 
killed by natural killer cells as they lack the MHC complex required to inhibit 
NK activity. They also lack any trace of Epstein-Barr virus and other 
herpesviruses. In addition to the Philadelphia chromosome they also exhibit a 
second reciprocal translocation between the long arm of chromosome 15 with 
chromosome 17.
Refer to the following optimal transfection conditions for maximal transfection 
efficiency on K562 cells.  GenJet reagent, 1.0 ml, is sufficient for 300 to 
600 transfections in 24 well plates or 50 to 100 transfections in 6 well plates.
| 
Summary of 
Optimal Transfection Conditions: | 
     | 
Storage Condition
Store at 4 °C. If stored properly, the product is stable for 12 months or longer
Data Sheet 

 

 
		
